Determination of a clinically important difference and definition of a responder threshold for the UCSD performance-based skills assessment (UPSA) in patients with major depressive disorder

被引:18
作者
Harvey, Philip D. [1 ]
Jacobson, William [2 ]
Zhong, Wei [2 ]
Nomikos, George G. [2 ]
Christensen, Michael Cronquist [3 ]
Olsen, Christina Kurre [3 ]
Merikle, Elizabeth [2 ]
机构
[1] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[2] Takeda Dev Ctr Amer, Deerfield, IL USA
[3] H Lundbeck & Co AS, Copenhagen, Denmark
关键词
Clinically important difference; UCSD Performance-Based Skills Assessment (UPSA); Major depressive disorder (MDD); Cognitive dysfunction; Functional capacity; QUALITY-OF-LIFE; MILD COGNITIVE IMPAIRMENT; FUNCTIONAL-CAPACITY; BIPOLAR DISORDER; FOLLOW-UP; SCHIZOPHRENIA; DISABILITY; SYMPTOMS; OUTCOMES; ASSOCIATION;
D O I
10.1016/j.jad.2017.02.014
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: This article reports an evaluation of the psychometric properties and clinically important difference (CID) threshold of the UCSD Performance-Based Skills Assessment (UPSA) in major depressive disorder (MDD), using data from a large-scale study of the effects of vortioxetine on cognitive functioning and functional capacity in MDD patients. Methods: Adults with moderate-to-severe recurrent MDD and self-reported cognitive dysfunction were randomized to 8 weeks of double-blind treatment with vortioxetine 10/20 mg QD (flexible), duloxetine 60 mg QD, or placebo. Pearson correlation coefficients were calculated between UPSA composite score and demographic/disease characteristics at baseline to examine construct validity. Two methods (distribution-based and anchor-based) were used to establish a CID threshold. Results: A total of 602 patients were randomized; 528 comprised the full analysis set. For the entire sample mean UPSA composite scores were 77.8 at baseline and 83.9 at week 8 (mean change, +6.1). As hypothesized, at baseline, the UPSA composite score correlated with cognitive functioning (Digit Symbol Substitution Test: r=0.36, P < 0.001) and workplace productivity (Work Limitations Questionnaire: r=-0.17, P=0.008), but not depressive symptoms (Montgomery-Asberg Depression Rating Scale: r=0.02, P=0.707) or subjective cognitive dysfunction (Perceived Deficits Questionnaire: r=-0.02, P=0.698). Limitations: Two versions of the UPSA were used and no inclusion/exclusion criteria were based on the UPSA. Conclusions: These results support the construct validity of UPSA for assessing functional capacity independent of mood symptoms. The estimated CID for changes in UPSA scores was quite consistent at +6.4 points and +6.7 based on distribution-based and anchor-based methods, respectively.
引用
收藏
页码:105 / 111
页数:7
相关论文
共 52 条
[1]   Low episodic memory performance as a premorbid marker of depression:: evidence from a 3-year follow-up [J].
Airaksinen, E. ;
Wahlin, A. ;
Forsell, Y. ;
Larsson, M. .
ACTA PSYCHIATRICA SCANDINAVICA, 2007, 115 (06) :458-465
[2]   Neurocognitive predictors of performance-based functional capacity in bipolar disorder [J].
Allen, Daniel N. ;
Bello, Danielle T. ;
Thaler, Nicholas S. .
JOURNAL OF NEUROPSYCHOLOGY, 2015, 9 (02) :159-171
[3]  
[Anonymous], 2014, SCHIZOPHRENIA RES CO
[4]   What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? [J].
Bandelow, Borwin ;
Baldwin, David S. ;
Dolberg, Ornah T. ;
Andersen, Henning Friis ;
Stein, Dan J. .
JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (09) :1428-1434
[5]   Combined Cognitive Remediation and Functional Skills Training for Schizophrenia: Effects on Cognition, Functional Competence, and Real-World Behavior [J].
Bowie, Christopher R. ;
McGurk, Susan R. ;
Mausbach, Brent ;
Patterson, Thomas L. ;
Harvey, Philip D. .
AMERICAN JOURNAL OF PSYCHIATRY, 2012, 169 (07) :710-718
[6]   Prediction of Real-World Functional Disability in Chronic Mental Disorders: A Comparison of Schizophrenia and Bipolar Disorder [J].
Bowie, Christopher R. ;
Depp, Colin ;
McGrath, John A. ;
Wolyniec, Paula ;
Mausbach, Brent T. ;
Thornquist, Mary H. ;
Luke, James ;
Patterson, Thomas L. ;
Harvey, Philip D. ;
Pulver, Ann E. .
AMERICAN JOURNAL OF PSYCHIATRY, 2010, 167 (09) :1116-1124
[7]   Determinants of real-world functional performance in schizophrenia subjects: Correlations with cognition, functional capacity, and symptoms [J].
Bowie, CR ;
Reichenberg, A ;
Patterson, TL ;
Heaton, RK ;
Harvey, PD .
AMERICAN JOURNAL OF PSYCHIATRY, 2006, 163 (03) :418-425
[8]   A summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia. [J].
Buchanan, RW ;
Davis, M ;
Goff, D ;
Green, MF ;
Keefe, RSE ;
Leon, AC ;
Nuechterlein, KH ;
Laughren, T ;
Levin, R ;
Stover, E ;
Fenton, W ;
Marder, SR .
SCHIZOPHRENIA BULLETIN, 2005, 31 (01) :5-19
[9]   Mediators of the association between depression and role functioning [J].
Buist-Bouwman, M. A. ;
Ormel, J. ;
de Graaf, R. ;
de Jonge, P. ;
van Sonderen, E. ;
Alonso, J. ;
Bruffaerts, R. ;
Vollebergh, W. A. M. .
ACTA PSYCHIATRICA SCANDINAVICA, 2008, 118 (06) :451-458
[10]  
Busner Joan, 2007, Psychiatry (Edgmont), V4, P28